PFO
HAE icon

Pathstone Family Office’s Haemonetics HAE Stock Holding History

Pathstone Family Office’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed – – 945
2020
Q4 		$0 Hold
2
– – ﹤0.01% 1223
2020
Q3 		$0 Sell
2
-2
-50% -$175 ﹤0.01% 881
2020
Q2 		$0 Buy
+4
New +$404 ﹤0.01% 825

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's HAE Position: Q1 2021 in Review

Pathstone Family Office sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 2 shares.

Pathstone Family Office first reported a position in HAE in Q2 2020 and held it in 3 quarters. The position peaked at $0 in Q4 2020. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

  • Pathstone Family Office reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 2 Haemonetics shares in Q1 2021.
  • Pathstone Family Office first reported a position in Haemonetics in Q2 2020 and held it in 3 quarters.
  • Pathstone Family Office's Haemonetics position peaked at $0 in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.